Durvalumab (IMFINZI®): Follow up Approval for NSCLC, a second indication, in USA

Durvalumab (IMFINZI®): Follow up Approval for NSCLC, a second indication, in USA

In February 2018, durvalumab (IMFINZI®) was approved in the US for the treatment of patients with unresectable, stage III non-small cell lung cancer (NSCLC), whose cancer has not progressed after chemoradiation therapy.[1] Continue reading “Durvalumab (IMFINZI®): Follow up Approval for NSCLC, a second indication, in USA”